NHRI licenses DBPR216, an anti-cancer developmental drug candidate, to Taivex Therapeutics Corp.

April 17, 2019 The National Health Research Institutes (NHRI) and Taivex Therapeutics Corp. (Taivex) are pleased to announce the technology transfer of DBPR216, a potential anti-cancer developmental drug candidate, effective April 8. NHRI’s licensing of DBPR216, a multi-targeted tyrosine kinase inhibitor, to Taivex will further the drug’s preclinical and clinical…

Continue reading

Identification of an upstream therapeutic target controlling IL-17A overproduction for autoimmune diseases

October 3, 2018 Autoimmune disease is the third of the top 10 catastrophic illnesses in Taiwan. An autoimmune disease is a condition that one’s immune system mistakenly attacks healthy cells or organs in one’s own body. Patients with autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, and…

Continue reading

Chinese Adaptation of the Ten-Item Internet Gaming Disorder Test (IGDT-10) and Prevalence Estimate of Internet Gaming Disorder among Adolescents in Taiwan

September 18, 2018   In June of 2018, the WHO officially classified Gaming Disorder as a psychiatric disorder, with the protests from major gaming companies worldwide. Players and people were generally confused: what does constitute internet gaming addiction? Is it just simply spending a lot of time playing? Dr. Yu-Hsuan…

Continue reading

Identification of metabolic pathways controlling breast cancer cell metastasis—New therapeutic strategies for triple negative breast cancer

July 17, 2018 Statistical data of Taiwan’s Ministry of Health and Welfare indicate that breast cancer is the leading cause of cancer death in women. Although common subtypes of breast cancer have a 5 years survival rate of over 85%, certain subtypes such as basal like triple negative breast cancer…

Continue reading